Shares of GSK plc (NYSE:GSK – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat reports. Six ...

GSK PLC closed 23.31% below its 52-week high of £18.24, which the company reached on May 16th.

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

Blue Trust Inc. lifted its position in GSK plc (NYSE:GSK – Free Report) by 16.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 12,505 shares of the pharmaceutical ...

GSK PLC closed 23.91% below its 52-week high of £18.24, which the company reached on May 16th.

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Select listed pharma player including Pfizer, Novartis India, AstraZeneca Pharma and GSK Pharma shall be the beneficiaries of ...